Disclaimer

This website is authorised by SYNthesis BioVentures Pty Ltd (ACN 657 562 162) (“SYNthesis BioVentures”), the investment manager of the SYNthesis BioVentures Fund I which is a stapled fund comprising SYNthesis BioVentures I, LP (ILP-L0000591U) (“ESVCLP Fund”), an Early Stage Venture Capital Limited Partnership, and the SYNthesis BioVentures Trust I (“Unit Trust”), an Australian unit trust. SYNthesis BioVentures is a Corporate Authorised Representative (AR 001296234) of Polar 993 Advisory Pty Ltd (ACN 649 554 932) (AFSL 531197) (“Polar Advisory”). The ESVCLP Fund is a complying and unconditionally registered early stage venture capital fund in accordance with the Venture Capital Act 2002 (Cth). Polar 993 Limited (ACN 642 129 226) (AFSL 525458) (“Polar 993”) is the trustee of the Unit Trust. SYNthesis BioVentures’ authority under its Corporate Authorised Representative Agreement with Polar Advisory is limited to general advice regarding the ESVCLP Fund and the Unit Trust, and only to wholesale clients. Polar 993 has entered into an Intermediary Authorisation Arrangement with SYNthesis BioVentures General Partner I, LP (AR 001296233) (“General Partner”), the general partner of the ESVCLP Fund, for the making of offers for the issuing, variation or disposal of interests in the ESVCLP Fund.